Henry Schein heads into late August with a notable split: the Street is raising targets after a solid earnings print, while short sellers are quietly adding back positions that were unwound last month.
The analyst community has been unusually active. BTIG lifted its target this week to $110 — a 10% jump from its prior $100 — while keeping a Buy rating, the most recent move in a string of upgrades following the Q2 beat. Barclays and Citigroup both raised targets earlier this month, to $100 and $112 respectively, with Citi's $112 the most bullish on the Street. UBS maintained its more cautious Neutral stance but nudged its target up to $94. The consensus price target is $98.19 against a current price of $89.23, implying roughly 10% upside — a constructive setup, though the gap is modest enough that execution needs to hold. Bulls point to market-share gains in dental distribution and the software platform buildout. Bears flag competition and lingering uncertainty around policy headwinds, though the Q2 numbers took some sting out of that argument.
The short picture tells a more mixed story. Short interest has climbed roughly 6.8% over the past week to 5.35% of free float — a noticeable rebound after a 10% decline over the prior month. The history is clear: shorts had been running near 7 million shares in mid-July, unwound meaningfully through early August around the earnings beat, and are now partially rebuilding. At 5.35% of float, this is a level worth watching but not extreme. Borrow conditions remain very relaxed — availability is running at approximately 896% of short interest, meaning there are nearly nine shares available to borrow for every one already shorted. Cost to borrow has crept up about 12% this week to 0.50%, its highest in recent weeks, but remains well within "easy borrow" territory. The lending market is offering no friction to new shorts.
Options positioning leans slightly bullish. The put/call ratio of 0.34 is just below its 20-day average of 0.35, with a z-score of -0.74 — well within normal range and nowhere near the defensive readings seen earlier in July when the PCR was running close to 0.38. The 52-week low on the PCR sits at 0.06, so there is room for sentiment to stretch further in either direction. For now, options traders are not adding protection.
KKR remains the standout institutional name with a 14% stake — unchanged from Q1. FMR (Fidelity) added over 1 million shares through June, and Dimensional Fund Advisors added 521,000 shares through July, both meaningful accumulations. The insider log is stale relative to today's date, with the most recent trade on record a director buy of 10,000 shares at $69.19 back in May — a price well below where the stock trades now. That trade looks well-timed in hindsight but doesn't reflect current positioning signals.
The next earnings event is penciled in for November 5. After the most recent Q2 print — which produced a one-day gain of roughly 3.6% — the focus will be on whether the operational efficiency narrative holds and whether the software segment can sustain its momentum. The short rebuild underway this week is the thread to follow: if it continues while the stock consolidates near $89, the tension between the bullish analyst consensus and the re-emerging bear positioning will sharpen considerably.
See the live data behind this article on ORTEX.
Open HSIC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
